Skip to main content
CXXIF
OTC Life Sciences

C21 Investments Q1 Loss Widens; Going Concern Risk Disclosed as Vireo Acquisition Nears Close

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.265
Mkt Cap
$57.884M
52W Low
$0.168
52W High
$0.537
52W Position info
58% above low
Off High info
51% below high
Rel. Volume info
3.4× avg
Market data snapshot near publication time

CXXIF sits 58% above its 52-week low of $0.168 on elevated volume (3.4× avg).

Summary

C21 Investments reported a wider Q1 loss and disclosed going concern risk, while confirming the Vireo Growth acquisition is expected to close today.


Key Events · Earnings and Guidance · CXXIF

  • Q1 Net Loss Widens

    Net loss was $1.97 million for the three months ended June 30, 2026, versus $0.76 million in the prior-year quarter.

  • Revenue Declines 10.8%

    Revenue fell to $7.63 million from $8.55 million, driven by price compression and increased competition in Nevada.

  • Going Concern Risk Disclosed

    The company states that changes in federal enforcement priorities could impact its ability to continue as a going concern.

  • Uncertain Tax Position Increases

    Uncertain tax position rose to $14.09 million from $13.36 million at March 31, 2026, related to Section 280E.


Analysis · CXXIF · Life Sciences

C21 Investments reported a net loss of $1.97 million for the quarter ended June 30, 2026, compared to a loss of $0.76 million a year earlier, as revenue fell 10.8% to $7.63 million. The company also disclosed going concern language related to federal cannabis enforcement uncertainty and an increased uncertain tax position of $14.09 million. The filing confirms the Vireo Growth acquisition is expected to close on August 21, 2026, which is today's date.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CXXIF was trading at $0.26 on OTC in the Life Sciences sector, with a market capitalization of approximately $57.9M. The 52-week trading range was $0.17 to $0.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CXXIF - Latest Insights

CXXIF
Jul 08, 2026, 8:47 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.233
Real-time Price: $0.2647 info
Change: +$0.0317 (+14%) info
Market Cap: $57.884M info
CXXIF
Jun 22, 2026, 2:24 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.25318
Real-time Price: $0.2647 info
Change: +$0.01152 (+5%) info
Market Cap: $57.884M info
CXXIF
Jun 15, 2026, 1:13 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.256
Real-time Price: $0.2647 info
Change: +$0.0087 (+3%) info
Market Cap: $57.884M info
CXXIF
Jun 12, 2026, 6:53 AM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $0.2761
Real-time Price: $0.2647 info
Change: -$0.0114 (-4%) info
Market Cap: $57.884M info
CXXIF
Jun 12, 2026, 6:02 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.2761
Real-time Price: $0.2647 info
Change: -$0.0114 (-4%) info
Market Cap: $57.884M info